{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:45:37Z","timestamp":1787222737426,"version":"build-2736575974"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the recent development of novel molecular targeted drugs for advanced stage malignant melanoma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>), including <jats:styled-content style=\"fixed-case\">RAF<\/jats:styled-content> and mitogen\u2010activated protein kinase kinase inhibitors and immune checkpoint blockers, the early detection of relapse is important for managing patients with <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>. In this study, we retrospectively analyzed two conventional serum biomarkers, 5\u2010S\u2010cysteinyl\u2010dopa and lactate dehydrogenase, in patients with <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 140) who were treated at a single Japanese institute from June 2007 to June 2015. At the initial hospital visit, serum 5\u2010S\u2010cysteinyl\u2010dopa levels were significantly increased in patients with stages <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 38) and <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 20) <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> compared with patients with stages 0\u2013<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 62) <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>. In addition, in patients with stages <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">IV MM<\/jats:styled-content>, serum 5\u2010S\u2010cysteinyl\u2010dopa levels of more than 15.0 nmol\/L at initial hospital visit correlated with a poor prognosis. In 11 of 14 patients whose disease progressed during follow up (mostly from stages <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\u2013<jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content>), serum 5\u2010S\u2010cysteinyl\u2010dopa levels exceeded the normal limit of 10.0 nmol\/L during the clinical detection of distant metastases. These results indicate the usefulness of measuring serum 5\u2010S\u2010cysteinyl\u2010dopa levels at initial hospital visit and during follow up for early and effective therapeutic interventions using newly developed molecular targeted drugs.<\/jats:p>","DOI":"10.1111\/1346-8138.13651","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T09:13:27Z","timestamp":1477559607000},"page":"449-454","source":"Crossref","is-referenced-by-count":17,"title":["Usefulness of serum 5\u2010S\u2010cysteinyl\u2010dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma"],"prefix":"10.1111","volume":"44","author":[{"given":"Hiroshi","family":"Umemura","sequence":"first","affiliation":[{"name":"Department of Dermatology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan"},{"name":"Melanoma Center Okayama University Hospital Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan"},{"name":"Melanoma Center Okayama University Hospital Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kaji","sequence":"additional","affiliation":[{"name":"Department of Dermatology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan"},{"name":"Melanoma Center Okayama University Hospital Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Division of Dermatology Shizuoka Cancer Center Hospital Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Asagoe","sequence":"additional","affiliation":[{"name":"Department of Dermatology National Hospital Organization Okayama Medical Center Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Takata","sequence":"additional","affiliation":[{"name":"Department of Dermatology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Iwatsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan"},{"name":"Melanoma Center Okayama University Hospital Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13257"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2424w"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp251"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-012-1409-5"},{"key":"e_1_2_6_7_1","first-page":"383","article-title":"Evaluating biomarkers in melanoma","volume":"4","author":"Karagiannis P","year":"2015","journal-title":"Front Oncol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/clinchem\/40.3.495","article-title":"Improved HPLC determination of 5\u2010S\u2010Cysteinyldopa in serum","volume":"40","author":"Wakamatsu K","year":"1994","journal-title":"Clin Chem"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-199106000-00009"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200206000-00008"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940201)73:3<629::AID-CNCR2820730321>3.0.CO;2-W"},{"key":"e_1_2_6_12_1","first-page":"5073","article-title":"Prognostic value of serum 5\u2010S\u2010Cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy","volume":"57","author":"Wimmer I","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2000.00710.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00487-2"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.1995.tb00653.x"},{"key":"e_1_2_6_16_1","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Prostate Cancer. Version.2.2014. Available from URL:http:\/\/www.nccn.org."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06096.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00922.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.467"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.09.007"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt027"},{"key":"e_1_2_6_22_1","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman S","year":"2014","journal-title":"Cancer Immunol Immunother"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13651","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.13651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:37:22Z","timestamp":1695472642000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.13651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/1346-8138.13651"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.13651","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]}}}